Chlamydia Trachomatis Prevalence and Screening Strategies

Chlamydia trachomatis is the most commonly reported bacterial sexually transmitted infection worldwide, with highest burden in young adults. Its capacity for asymptomatic carriage in both women and men fosters silent transmission, leading to complications such as pelvic inflammatory disease, ectopic pregnancy and infertility. Surveillance data reveal persistent or rising prevalence in many regions despite established control efforts. Screening strategies range from population-based surveys to opportunistic testing in clinical settings, targeting sexually active individuals under 25 years of age and other high-risk groups. Programmes employ nucleic acid amplification tests (NAATs) on urine or swab specimens to detect infections efficiently. Modelling studies indicate that regular screening and prompt treatment can reduce average duration of infection, although optimal frequency, coverage and cost-effectiveness remain under evaluation. Integrating behavioural interventions, partner notification and tailored outreach in underserved populations is pivotal to interrupt transmission chains and mitigate long-term sequelae.

Research from Nature Portfolio

National cross-sectional surveys in the United States have documented a significant rise in chlamydia prevalence among 18–39-year-olds, from approximately 1.6% in 2005–2010 to 1.9% in 2011–2016. Increases were most pronounced in males aged 18–29, non-Hispanic Black individuals and those reporting early age at first intercourse or multiple lifetime partners. Logistic regression analyses highlight socio-demographic and behavioural determinants, underscoring the need for annual screening of sexually active young adults. These findings also suggest that expanding testing beyond women to include young men could enhance early detection and treatment, thereby reducing overall community prevalence and associated reproductive health complications.

Chlamydia Trachomatis Prevalence and Screening Strategies publication trend

The graph below shows the total number of articles in chlamydia trachomatis prevalence and screening strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Prevalence: The proportion of a defined population with chlamydia infection at a given time.

Asymptomatic infection: Presence of Chlamydia trachomatis without observable signs or symptoms.

Opportunistic screening: Offering chlamydia testing to individuals during routine healthcare visits regardless of symptomatology.

Nucleic acid amplification test (NAAT): A molecular assay that detects C. trachomatis DNA or RNA with high sensitivity and specificity.

Cross-sectional survey: An observational study measuring infection status and risk factors in a population at a single point in time.

References

1. Trends in chlamydia prevalence in the United States, 2005–2016. Scientific Reports (2024).
2. Chlamydia Trachomatis Prevalence in Asymptomatic Women in Madrid: Study Findings and Their Association with Risk Factors and Mental Health. Biomedicines (2024).
3. Prevalence of and risk factors for chlamydia in female outpatients with genital tract infections: a nationwide multi-center, cross-sectional study in China. Frontiers in Public Health (2023).